Featured Research

from universities, journals, and other organizations

Intravenously administered ketamine shown to reduce symptoms of chronic post-traumatic stress disorder

Date:
April 16, 2014
Source:
Mount Sinai Medical Center
Summary:
For the first time, evidence that a single dose of IV-administered ketamine was associated with the rapid reduction of symptoms of post-traumatic stress disorder in patients with chronic PTSD was demonstrated in a proof-of-concept, randomized, double blind crossover study. These findings could be the first step toward developing new interventions for PTSD.

For the first time, evidence that a single dose of IV-administered ketamine was associated with the rapid reduction of symptoms of post-traumatic stress disorder in patients with chronic PTSD was demonstrated in a proof-of-concept, randomized, double blind crossover study, undertaken by researchers at the Icahn School of Medicine at Mount Sinai in New York City. These findings, according to Mount Sinai researchers, could be the first step toward developing new interventions for PTSD.

The original investigation, titled "Efficacy of Intravenous Ketamine for Treatment of Chronic Post-Traumatic Stress Disorder -- A Randomized Clinical Trial," was first published online in JAMA Psychiatry on April 16.

"These findings may lead to novel approaches in the treatment of chronic PTSD -- a condition that affects a broad spectrum of adults in the United States and beyond, including victims of sexual assault, war veterans, those who have witnessed catastrophic events such as the September 11 terror attacks, and others," said Adriana Feder, MD, Associate Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai and the lead author of the study. "However, this should be viewed as a proof of concept study. Additionally, longer term clinical trials with ketamine will be required to determine if ketamine will be a clinically useful treatment for PTSD."

Previously, few pharmacotherapies, such as selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors -- both of which are associated with significant levels of nonresponse and persistent residual symptoms of post-traumatic stress disorder -- have been shown to be effective in the treatment of chronic PTSD. However, these treatments were not shown to have the same rapid effects on symptoms of PTSD as IV-administered ketamine, which emerged as an effective, quick-acting intervention for patients with treatment-resistant depression when administered at sub-anesthetic doses (0.5 mg / kg).

Ketamine is used for anesthesia at doses of 2 mg/kg or higher, and as an analgesic (painkiller) at subanesthetic doses. It is considered particularly safe because, unlike other anesthetics, ketamine reliably preserves breathing reflexes. According to Mount Sinai's researchers, there have been no randomized clinical trials examining the effects of ketamine in patients with chronic PTSD; the few previous studies that have examined the effects of ketamine in trauma-exposed individuals were either retrospective or non-randomized.

"In recent years, we and others have shown that ketamine could often counter the symptoms of depression in treatment-resistant cases. In the present study, we hypothesized that ketamine would be associated with significantly greater reduction in core PTSD symptom levels 24 hours after a single IV infusion, and that it would also improve co-morbid depressive symptoms in patients diagnosed with PTSD," said Dennis Charney, MD, Anne and Joel Ehrenkranz Dean, Icahn School of Medicine at Mount Sinai, President for Academic Affairs, Mount Sinai Health System, and principal investigator. "This study has borne out that hypothesis, and we hope the results soon will be replicated and extended by other researchers."

Study Methodology Patients with chronic PTSD were enrolled in this study at the Icahn School of Medicine at Mount Sinai between May, 2012 and December 2012. Eligible participants were between 18 and 55 years of age; had a primary diagnosis of PTSD; and a score of at least 50 on the Clinician-Administered PTSD Scale (CAPS). Study participants were free of concomitant psychotropic medications for two weeks prior to randomization and for the duration of the study.

For each procedure day, patients were assigned to receive a single IV infusion of ketamine hydrochloride or midazolam administered over 40 minutes. The order of infusions was randomly assigned, and administrations were made two weeks apart. Midazolam was chosen as the active placebo because its pharmacokinetic parameters and nonspecific behavioral effects are similar to those of ketamine.

Administered ratings were administered at pre-infusion baseline and 24 hours (day 1) after infusion (before patients were discharged from the hospital), 48 hours (day 2) after infusion, 72 hours (day 3) after infusion, and seven days day 7) after infusion.

The primary outcome was PTSD symptom severity 24 hours after infusion, assessed with the Impact of Event Scale -- Revised (IES -- R). Total IES-R scores 24 hours after infusion were significantly improved with ketamine compared with midazolam (mean difference, 12.7 [95% CI, 2.5-22.8]; P = .02). There was no evidence of any period or residual effects for the crossover. Additionally, symptoms in seven patients randomly assigned to ketamine first remained significantly reduced two weeks after infusion, compared with only one patient randomly assigned to midazolam first.


Story Source:

The above story is based on materials provided by Mount Sinai Medical Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. Adriana Feder, Michael K. Parides, James W. Murrough, Andrew M. Perez, Julia E. Morgan, Shireen Saxena, Katherine Kirkwood, Marije aan het Rot, Kyle A. B. Lapidus, Le-Ben Wan, Dan Iosifescu, Dennis S. Charney. Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress Disorder. JAMA Psychiatry, 2014; DOI: 10.1001/jamapsychiatry.2014.62

Cite This Page:

Mount Sinai Medical Center. "Intravenously administered ketamine shown to reduce symptoms of chronic post-traumatic stress disorder." ScienceDaily. ScienceDaily, 16 April 2014. <www.sciencedaily.com/releases/2014/04/140416172000.htm>.
Mount Sinai Medical Center. (2014, April 16). Intravenously administered ketamine shown to reduce symptoms of chronic post-traumatic stress disorder. ScienceDaily. Retrieved August 22, 2014 from www.sciencedaily.com/releases/2014/04/140416172000.htm
Mount Sinai Medical Center. "Intravenously administered ketamine shown to reduce symptoms of chronic post-traumatic stress disorder." ScienceDaily. www.sciencedaily.com/releases/2014/04/140416172000.htm (accessed August 22, 2014).

Share This




More Mind & Brain News

Friday, August 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Lost Brain Cells To Blame For Sleep Problems Among Seniors

Lost Brain Cells To Blame For Sleep Problems Among Seniors

Newsy (Aug. 21, 2014) According to a new study, elderly people might have trouble sleeping because of the loss of a certain group of neurons in the brain. Video provided by Newsy
Powered by NewsLook.com
Do More Wedding Guests Make A Happier Marriage?

Do More Wedding Guests Make A Happier Marriage?

Newsy (Aug. 20, 2014) A new study found couples who had at least 150 guests at their weddings were more likely to report being happy in their marriages. Video provided by Newsy
Powered by NewsLook.com
Charter Schools Alter Post-Katrina Landscape

Charter Schools Alter Post-Katrina Landscape

AP (Aug. 20, 2014) Nine years after Hurricane Katrina, charter schools are the new reality of public education in New Orleans. The state of Louisiana took over most of the city's public schools after the killer storm in 2005. (Aug. 20) Video provided by AP
Powered by NewsLook.com
Researcher Testing on-Field Concussion Scanners

Researcher Testing on-Field Concussion Scanners

AP (Aug. 19, 2014) Four Texas high school football programs are trying out an experimental system designed to diagnose concussions on the field. The technology is in response to growing concern over head trauma in America's most watched sport. (Aug. 19) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins